Cite
Andrade YCP, Ropke J, Viana TG, et al. Effects of JL13, a pyridobenzoxazepine compound, in dopaminergic and glutamatergic models of antipsychotic activity. Behav Pharmacol. 2021;32(1):2-8doi: 10.1097/FBP.0000000000000595.
Andrade, Y. C. P., Ropke, J., Viana, T. G., Fanelli, C., Minaldi, E., Batista, L. A., Issy, A. C., Del Bel, E. A., Rodrigues, L. C. M., Liégeois, J. F., & Moreira, F. A. (2021). Effects of JL13, a pyridobenzoxazepine compound, in dopaminergic and glutamatergic models of antipsychotic activity. Behavioural pharmacology, 32(1), 2-8. https://doi.org/10.1097/FBP.0000000000000595
Andrade, Yane C P, et al. "Effects of JL13, a pyridobenzoxazepine compound, in dopaminergic and glutamatergic models of antipsychotic activity." Behavioural pharmacology vol. 32,1 (2021): 2-8. doi: https://doi.org/10.1097/FBP.0000000000000595
Andrade YCP, Ropke J, Viana TG, Fanelli C, Minaldi E, Batista LA, Issy AC, Del Bel EA, Rodrigues LCM, Liégeois JF, Moreira FA. Effects of JL13, a pyridobenzoxazepine compound, in dopaminergic and glutamatergic models of antipsychotic activity. Behav Pharmacol. 2021 Feb 01;32(1):2-8. doi: 10.1097/FBP.0000000000000595. PMID: 33399294.
Copy
Download .nbib